The authors investigated the clinical significance of LA strain analysis in the prediction of future CTRCD after additional trastuzumab therapy in patients with HER2-positive breast cancer who did not develop CTRCD after standard chemotherapy, and the present study demonstrated several clinically important findings. The gene discussed is ERBB2; the disease is breast carcinoma.